

Davidson, Mark

From: Davidson, Mark
Sent: Friday, July 07, 2017 11:52 AM
To: 'Rizwana Sproule'
Cc: 'Nadia Agopyan'; 'Alex Babayan'
Subject: Kite Pharma BLA 125643 Clinical Information request July 7, 2017

Importance: High

Dear Dr. Sproule,

Reference is made to the 7/5/2017 information request to provide PFS sensitivity analysis data in ADTTE.xpt. You responded that "this sensitivity analysis was felt to be of limited value and was not reported." To reiterate, for the efficacy review, submit a revised ADTTE.xpt is that contains both the DOR sensitivity analysis and PFS sensitivity analysis, each per investigator and IRC, in which censoring occurs at the time of ASCT. Note, per the 7/6/2017 statistical information request, that censoring for DOR (as with PFS) is to occur at the time of ASCT, not last disease assessment prior to ASCT.

Submit the revised data by 12 pm EST, Monday July 10, 2017.

Thank You

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."